Delving into the Latest Updates on Materia Medica Holding Research And Production Company with Synapse

Multicenter Double-blind Placebo-controlled Randomized Clinical Trial of the Efficacy and Safety of Tenoten for Children in 12-week Treatment of Children With Anxiety Disorders

Purpose of the study:
• evaluate the efficacy and safety of Tenoten for children in children with anxiety disorders.

开始日期2010-07-28

申办/合作机构

Materia Medica Holding Research And Production Company

100 项与 Materia Medica Holding Research And Production Company 相关的临床结果

登录后查看更多信息

0 项与 Materia Medica Holding Research And Production Company 相关的专利（医药）

登录后查看更多信息

5

项与 Materia Medica Holding Research And Production Company 相关的文献（医药）

2019-04-01·Bulletin of Experimental Biology and Medicine4区 · 医学

Ergoferon Increases IL-2 Production by Activated Lymphocytes

4区 · 医学

Article

作者: Emel'yanova, A G ; Petrova, A O ; Gorbunov, E A ; Kanareikina, M A ; Tarasov, S A ; Alinkina, E S

We studied the effects of Ergoferon on the production of antiviral cytokine IL-2 by type 1 CD4⁺T cells. Preincubation of Jurkat cells with Ergoferon increased IL-2 secretion by these cells after stimulation with phorbol 12-myristate 13-acetate/ionomycine in comparison with the placebo group. The data prove that Ergoferon is capable of activating cell cascades involved in the realization of the antiviral immune response.

2017-01-01·Bulletin of Experimental Biology and Medicine4区 · 医学

Effects of Release-Active Antibodies to CD4 Receptor on the Level of lck-Kinase in Cultured Mononuclear Cells from Human Peripheral Blood

4区 · 医学

Article

作者: Petrova, N V ; Khaitov, M R ; Tarasov, S A ; Emel'yanova, A G ; Morozov, S G ; Grechenko, V V ; Gorbunov, E A ; Epshtein, O I ; Shilovskii, I P

For evaluation of effects of release-active antibodies to CD4 on cultured lymphocytes from human peripheral blood, we measured intracellular content of lck-kinase cell-based ELISA. In cells treated with release-active antibodies to CD4, the content of intracellular lck-kinase significantly (p<0.01) decreased in comparison with the control (purified water processed in a similar way). Phytohemagglutinin had no effect on the concentration of lck-kinase in cells. The decrease in the content of CD4-associated lck protein suggests that the preparation enhanced intracellular coupling of lck-kinase with T-cell receptor and potentiated T-cell immune response.

2005-01-01·International journal of tissue reactions

A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.

Article

作者: Tcherevkova, E V ; Epstein, O I ; Petrov, V I ; Martyushev-Poklad, A V ; Babayeva, A R ; Dugina, J L ; Sergeeva, S A

Artrofoon (oral ultra-low doses of antibodies to TNF-alpha is a novel drug approved by the Russian Ministry of Health for the treatment of rheumatoid arthritis (RA). The aim of this study was to assess clinical efficacy and safety of artrofoon in RA compared with diclofenac. In a 6-month, randomized, open-label, comparative trial, 60 patients with active RA (eight men and 52 women aged 23 to 62, mean disease duration 10 years) received artrofoon (8 tablets daily, n = 30) or diclofenac (100 mg daily, n = 30). RA signs and symptoms as well as serum levels of inflammatory markers were evaluated before treatment and at months 1, 3 and 6. Most patients in the artrofoon group showed a 20% improvement in major RA symptoms by the end of the study. The clinical effect rose gradually reaching maximum at month 6. In the artrofoon group, 57% of the patients achieved an American College of Rheumatology (ACR) 20% criteria (ACR20) by month 6 versus 20% of those receiving diclofenac. In some patients in the artrofoon arm, serum proinflammatory cytokine levels significantly decreased (> or = 25% reduction). Diclofenac produced a less pronounced clinical effect, and no changes in cytokine profile. Unlike conventional nonsteroidal anti-inflammatory drugs, artrofoon produced no adverse effects and the overall tolerability and safety were excellent. A half-dose treatment with artrofoon (4 tablets daily) was able to sustain clinical improvements over a 6-month follow-up period. To conclude, artrofoon is a safe and effective treatment for rheumatoid arthritis that acts by influencing the inflammatory process.

100 项与 Materia Medica Holding Research And Production Company 相关的药物交易

登录后查看更多信息

100 项与 Materia Medica Holding Research And Production Company 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

6

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Kolofort ( TNF-α )	肠易激综合征更多	批准上市
Rengalin	咳嗽更多	批准上市
Afala ( KLK3 )	前列腺癌更多	批准上市
Ergoferon(Materia Medica Holding Research And Production Company)	流感病毒感染更多	批准上市
Anti-tumour necrosis factor-alpha antibody(Materia Medica Holding Research And Production Company) ( TNF-α )	骨关节炎更多	批准上市